-
Mar 20 |
Diagnostics World | GE HealthCare announced a collaboration this week with NVIDIA, expanding the existing 16-year relationship between the two companies to focus on pioneering innovation in autonomous imaging, beginning with autonomous X-ray technologies and autonomous applications within ultrasound.
More
-
Mar 19 |
Diagnostics World | Based on the discovery that the adhesion strength of cancer cells scales inversely proportional to the invasiveness of a tumor, researchers at University of California, San Diego have built a microfluidic device with the hope that it can be used in the future to diagnose the metastatic potential of ductal carcinoma in situ (DCIS) breast cancer tumors.
More
-
Mar 18 |
Diagnostics World | The incidence of bladder cancer is rising significantly due to population aging and, while survival rates are relatively high, when diagnosed late patients may need to undergo bladder removal regardless of survival. Early detection and treatment of bladder cancer are therefore crucial to preserving the organ and maintaining the patient’s quality of life.
More
-
Mar 13 |
Diagnostics World | Altitude Lab, a nonprofit established by biotech company Recursion, has launched a pre-seed venture fund aimed at supporting 10 to 15 early-stage startups navigating the current uncertainty surrounding government funding. Executive Director Chandana Haque hopes other private investment groups will follow suit to bridge the gap left by disrupted Small Business Innovation Research (SBIR) grants, which have historically been crucial in launching startups and securing follow-on investments.
More
-
Mar 11 |
Diagnostics World | A new platelet function test has been developed by researchers in the UK that could help pharmaceutical companies design better, safer drugs for the prevention of heart attacks and strokes and, longer term, to help doctors know which of their high-risk patients should be put on blood thinners. Ultimately, the test could be developed into a point-of-care preventive diagnostic for the general population that’s as simple to use as a blood glucose fingerprick test.
More
-
Mar 06 |
Diagnostics World | A retrospective study from Personalis for its NeXT Personal test, an ultra-sensitive circulating tumor DNA (ctDNA) test for cancer patients and survivors, has been published in Annals of Oncology. The study was conducted with researchers from The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust in the UK.
More
-
Mar 05 |
Diagnostics World | In a paper published last month in Nature Scientific Reports, authors validate Northstar Response, BillionToOne's novel tissue-free circulating tumor DNA (ctDNA) liquid biopsy test that enables physicians to monitor cancer treatment response in Stage III-IV cancers with a blood draw.
More
-
Mar 04 |
Diagnostics World | A transcontinental collaborative effort brought together 300 experts from 12 European countries and Canada to try and crack the genetic cause of thousands of unsolved rare disease cases. Through data-sharing and genetic reanalysis, this “coalition of the willing” has most recently succeeded in providing more than 500 patients with a long-awaited diagnosis—and peace of mind to unaffected family members about whether they carry the risk variant.
More
-
Feb 27 |
Diagnostics World | Dovetail Genomics announced its early access services for FFPE (Formalin-Fixed Paraffin-Embedded) sample analysis; Cellino announced its collaboration with Mass General Brigham’s Gene and Cell Therapy Institute (GCTI) to launch the world’s first hospital-based autologous induced pluripotent stem cell (iPSC) Foundry; and more.
More
-
Feb 26 |
Diagnostics World | A transcontinental collaborative effort brought together 300 experts from 12 European countries and Canada to try and crack the genetic cause of thousands of unsolved rare disease cases. Through data-sharing and genetic reanalysis, this “coalition of the willing” has most recently succeeded in providing more than 500 patients with a long-awaited diagnosis—and peace of mind to unaffected family members about whether they carry the risk variant.
More
-
Mar 24 |
Anthos Therapeutics, Inc., a business that produces abelacimab (full human monoclonal antibody), a late-stage medication being developed to prevent stroke and systemic embolism in patients with atrial fibrillation, has agreed to be acquired by Novartis. Upon concluding the deal, Novartis will pay $925 million upfront, subject to certain usual adjustments. If certain sales and regulatory milestones are met, Novartis may also pay an additional $2.15 billion.
More
-
Mar 21 |
Coronado Research has appointed Gary Lyons as EVP Medical Affairs. Gary is a seasoned senior Medical Affairs leader with extensive strategic and operational implementation experience across the industry and product lifecycle.
More
-
Mar 20 |
Funding led by global software investor Insight Partners comes as the surge in cancer cases compounds the impact of the shrinking pathologist workforce.
More
-
Mar 19 |
Diasorin announced the availability of its Simplexa C. Auris Direct kit in all countries accepting the CE mark. The targeted molecular diagnostic test is performed on the LIAISON MDX instrument, yielding patient results in less than two hours.
More
-
Mar 19 |
More
-
Mar 19 |
START's site network solidifies its global leadership in urological cancer trials.
More
-
Mar 14 |
Coronado Research has appointed Nick Littlebury as EVP, Regulatory Affairs. Nick is a senior regulatory leader with extensive strategic and operational experience across the pharmaceutical industry's product lifecycle.
More
-
Mar 14 |
As Baylor Genetics celebrates a decade of leadership at the forefront of genetic testing, it is set to exhibit its latest scientific studies in genetic testing at the 2025 ACMG Annual Clinical Genetics Meeting, taking place March 18-22, 2025, in Los Angeles, CA. The Company will be located at Booth #217 at the Los Angeles Convention Center.
More
-
Mar 13 |
More
-
Mar 13 |
ClearNote Health announced an agreement with Claritev, Inc., (previously MultiPlan, Inc.) that will make ClearNote Health’s Avantect Pancreatic Cancer Test available to health plan members accessing Claritev’s national PHCS and MultiPlan Networks.
More
View more articles